Comparison
Ketamine vs psilocybin (research-stage)
Psilocybin is an investigational psychedelic with active depression research. Ketamine is legally available in clinical settings; psilocybin is not, outside research and limited regulated programs.
Medically reviewed by: Pending medical review(draft)Last updated: June 4, 2026Evidence: Educational synthesis - not medical advice
Ketamine
Psilocybin
Mechanism
NMDA-receptor antagonism.
Serotonin 5-HT2A receptor agonism.
Evidence
Clinical use today; active research.
Phase 2/3 research; not FDA-approved as of mid-2026 for general depression treatment.
Onset
Hours to days.
Often within days to weeks after a session, in research settings.
Duration
Days to weeks.
Weeks to months in studies.
Side effects
Dissociation, BP changes, nausea.
Anxiety, perceptual changes, nausea; longer duration of acute effects.
Access
Specialty clinics today.
Research, Oregon/Colorado regulated programs, and limited international contexts.
Best for
Patients seeking a clinically available rapid-acting option.
Research participants or patients in regulated programs; not a substitute for clinical care.
Limits
Cost, durability, access.
Legal status, limited access, longer sessions.
Educational use only. The content on this page is provided for general educational purposes and does not constitute medical advice, diagnosis, or treatment. Ketamine and related therapies carry risks and are appropriate only under qualified medical supervision. Always consult a licensed healthcare professional about your individual situation. Information may change as research evolves.